Company Encyclopedia
View More
name
Integra LifeSciences
IART.US
Integra LifeSciences Holdings Corporation manufactures and sells surgical instrument, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices.
1.407 T
IART.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
Health Care EquipmentIndustry
Industry Ranking120/171
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-38.71%E
    • Profit Margin-30.15%E
    • Gross Margin57.16%B
  • Growth ScoreD
    • Revenue YoY4.99%C
    • Net Profit YoY-7468.14%E
    • Total Assets YoY-10.31%E
    • Net Assets YoY-31.81%E
  • Cash ScoreD
    • Cash Flow Margin-331.69%D
    • OCF YoY4.99%C
  • Operating ScoreC
    • Turnover0.43C
  • Debt ScoreD
    • Gearing Ratio71.55%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Integra Brief: Q3 Net loss of US$8.2 million, or $0.05 loss per share

    Integra Brief: Q3 Net loss of US$8.2 million, or $0.05 loss per share

    marketscreener·
    US
    IART
    +0.59%
    marketscreener·
    US
    IART
    +0.59%

    Director Makes Bold Move with Major Stock Purchase in Integra Lifesciences

    Director Jeffrey Graves of Integra Lifesciences (IART) purchased 9,000 shares worth $102,150 on November 6, 2025. The company faces challenges, including a revenue miss in Q3, leading to mixed updates on stock price targets from various analysts. Truist lowered its target, while JPMorgan raised it, and Citi also reduced its target due to ongoing issues. Despite a 5% organic revenue growth, the company revised its full-year guidance downward. Overall, the sentiment on IART stock remains cautious, with a Neutral rating from TipRanks' AI Analyst.

    Tip Ranks·
    US
    IART
    +0.59%
    Tip Ranks·
    US
    IART
    +0.59%

    Director Jeffrey A. Graves Acquires Common Shares of Integra LifeSciences Holdings Corporation

    Director Jeffrey A. Graves has acquired common shares of Integra LifeSciences Holdings Corporation. The full filing is available through the provided link. This news was generated by Public Technologies and is for informational purposes only, not to be considered as financial, investment, or legal advice. The original content was published by Integra LifeSciences Holdings Corporation via EDGAR on November 06, 2025.

    Reuters·
    US
    IART
    +0.59%
    Reuters·
    US
    IART
    +0.59%

    Integra LifeSciences Earnings Call: Mixed Sentiment and Strategic Advancements

    Integra LifeSciences' recent earnings call revealed mixed sentiment, showcasing operational successes alongside challenges. The company reported a 5% organic revenue growth, with total revenues of $402 million and an adjusted EPS of $0.54, exceeding guidance. However, supply chain disruptions and challenges in the ENT and Private Label segments led to a lowered full-year guidance of $1.62 billion to $1.64 billion. Despite a gross margin decline to 62.9%, the company anticipates modest growth in 2026, driven by strategic initiatives and cost-saving measures.

    Tip Ranks·
    US
    IART
    +0.59%
    Tip Ranks·
    US
    IART
    +0.59%

    Integra Lifesciences (IART) Receives a Sell from Morgan Stanley

    Wood covers the Healthcare sector, focusing on stocks such as TransMedics Group, Becton Dickinson, and Zimmer Biomet Holdings. According to TipRanks, Wood has an average return of -0.5% and a 52.90% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Sell analyst consensus rating for Integra Lifesciences with a $14.60 average price target, which is a 22.69% upside from current levels. In a report released today, Citi also maintained a Sell rating on the stock with a $11.00 price target.

    Tip Ranks·
    US
    IART
    +0.59%
    Tip Ranks·
    US
    IART
    +0.59%
    © 2025 Longbridge｜Disclaimer